Akero Therapeutics (NASDAQ:AKRO) Receives New Coverage from Analysts at Evercore ISI
Evercore ISI initiated coverage on shares of Akero Therapeutics (NASDAQ:AKRO) in a report released on Monday morning, Briefing.com Automated Import reports. The firm issued an outperform rating and a $35.00 target price on the stock.
AKRO has been the subject of a number of other research reports. Jefferies Financial Group set a $189.00 price objective on shares of salesforce.com and gave the company a buy rating in a report on Monday. Roth Capital restated a buy rating on shares of Coeur Mining in a report on Monday. Finally, JPMorgan Chase & Co. restated a sell rating and set a $18.00 price objective on shares of ABB in a report on Monday.
Shares of NASDAQ AKRO opened at $21.55 on Monday. Akero Therapeutics has a 52-week low of $16.06 and a 52-week high of $21.94.
About Akero Therapeutics
Akero Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development and commercialization of transformative treatments for serious metabolic diseases with high unmet medical need. Its lead product candidate is AKR-001, which completed Phase Ib clinical trial for the treatment of non-alcoholic steatohepatitis disease.
Recommended Story: How to Trade Using Analysts Ratings
Receive News & Ratings for Akero Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akero Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.